甲基荷兰胺治疗诱导可逆心脏损伤和心肌细胞基因表达
Christine Bode1, Sebastian Preissl1, Lutz Hein1,2
1Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Intensive care medicine experimental
|May 11, 2024
概括
长时间的甲基荷胺治疗可能会导致心脏重塑,但在停止药物后,这些变化是可逆的. 这项研究揭示了分子机制和潜在的治疗点,以控制甲基荷胺的副作用.
科学领域:
- 心血管医学 心血管医学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在重症监护中,catecholamines对于在休克期间维持器官输液至关重要.
- 然而,过度的上腺激活可以导致有害的心脏重塑和心力衰竭.
- 在没有心力衰竭的情况下,catecholamine治疗对心脏损伤的长期影响仍然不清楚.
研究的目的:
- 评估心脏重塑和恢复期间和长期治疗catecholamine后.
- 为了研究白色素胺诱导的心脏变化的潜在分子机制.
- 探索潜在的治疗目标,以减轻不良影响.
主要方法:
- 在C57BL/6N小鼠中进行了为期14天的甲醇胺治疗 (异二烯和二烯).
- 隔离心肌细胞核的RNA测序以分析基因表达.
- 对增强体区域的DNA甲基化分析以确定关键的转录因子.
主要成果:
- 甲基荷胺治疗改善了收缩能力,但引起了可逆心脏纤维化和缩.
- 基因表达分析揭示了细胞外基质和TGF信号通路的暂时上调.
- 确定了上腺和内甲素-1信号通路之间的交叉声,其中AP-1转录因子 (Jun,Fos) 作为关键驱动因素.
结论:
- 长时间暴露于甲基荷胺会导致心脏重塑和改变基因表达在左心室功能障碍之前.
- 观察到的心脏变化在很大程度上可以在停止治疗后逆转.
- 与内分泌蛋白信号传递和已识别的转录因子的交叉声提供了新的治疗途径.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:26Heart Failure Drugs: Inotropic Agents
573
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
573
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
740
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
740